UniProtKB/Swiss-Prot P02545 : Variant p.Arg298Cys
Prelamin-A/C
Gene: LMNA
Feedback ?
Variant information
Variant position:
298
The position of the amino-acid change on the UniProtKB canonical protein sequence.
Type of variant:
LP/P [Disclaimer : Variants classification is intended for research purposes only, not for clinical and diagnostic use . The label disease variant is assigned according to literature reports on probable disease-association that can be based on theoretical reasons. This label must not be considered as a definitive proof for the pathogenic role of a variant. ]
The variants are classified into three categories: LP/P, LB/B and US.LP/P: likely pathogenic or pathogenic. LB/B: likely benign or benign. US: uncertain significance
Residue change:
From Arginine (R) to Cysteine (C) at position 298 (R298C, p.Arg298Cys).
Indicates the amino acid change of the variant. The one-letter and three-letter codes for amino acids used in UniProtKB/Swiss-Prot are those adopted by the commission on Biochemical Nomenclature of the IUPAC-IUB.
Physico-chemical properties:
Change from large size and basic (R) to medium size and polar (C)
The physico-chemical property of the reference and variant residues and the change implicated.
BLOSUM score:
-3
The score within a Blosum matrix for the corresponding wild-type to variant amino acid change. The log-odds score measures the logarithm for the ratio of the likelihood of two amino acids appearing by chance. The Blosum62 substitution matrix is used. This substitution matrix contains scores for all possible exchanges of one amino acid with another: Lowest score: -4 (low probability of substitution).Highest score: 11 (high probability of substitution). More information can be found on the following page
Variant description:
In CMT2B1.
Any additional useful information about the variant.
Other resources:
Links to websites of interest for the variant.
Sequence information
Variant position:
298
The position of the amino-acid change on the UniProtKB canonical protein sequence.
Protein sequence length:
664
The length of the canonical sequence.
Location on the sequence:
AERNSNLVGAAHEELQQSRI
R IDSLSAQLSQLQKQLAAKEA
The residue change on the sequence. Unless the variant is located at the beginning or at the end of the protein sequence, both residues upstream (20) and downstream (20) of the variant will be shown.
Residue conservation:
The multiple alignment of the region surrounding the variant against various orthologous sequences.
Human AERNSNLVGAAHEELQQSRIR IDSLSAQLSQLQKQLAAKEA
Mouse AERNSNLVGAAHEELQQSRIR IDSLSAQLSQLQKQLAAKEA
Rat AERNSNLVGAAHEELQQSRIR IDSLSAQLSQLQKQLAAKEA
Pig AERNSNLVGAAHEELQQSRIR IDSLSAQLSQLQKQLAAKEA
Chicken AERNSSMAGAAHEELQQTHIR IDSLSAELSQLQKQLAAKEA
Xenopus laevis AERNSSLVGEAQEEIQQSRIR IDSLSAQLSQLQKQLAAREA
Sequence annotation in neighborhood:
The regions or sites of interest surrounding the variant. In general the features listed are posttranslational modifications, binding sites, enzyme active sites, local secondary structure or other characteristics reported in the cited references. The "Sequence annotation in neighborhood" lines have a fixed format:Type: the type of sequence feature. Positions: endpoints of the sequence feature. Description: contains additional information about the feature.
Type Positions Description
Chain
1 – 661
Prelamin-A/C
Chain
1 – 646
Lamin-A/C
Domain
31 – 387
IF rod
Region
243 – 383
Coil 2
Region
259 – 331
Necessary and sufficient for the interaction with IFFO1
Modified residue
282 – 282
Phosphoserine; by ATR
Modified residue
301 – 301
Phosphoserine
Modified residue
307 – 307
Phosphoserine
Modified residue
311 – 311
N6-acetyllysine
Modified residue
316 – 316
N6-acetyllysine
Cross
311 – 311
Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO2); alternate
Mutagenesis
282 – 282
S -> A. Impaired phosphorylation by ATR in response to DNA damage, leading to decreased nuclear envelope rupture.
Helix
244 – 335
Literature citations
Homozygous defects in LMNA, encoding lamin A/C nuclear-envelope proteins, cause autosomal recessive axonal neuropathy in human (Charcot-Marie-Tooth disorder type 2) and mouse.
De Sandre-Giovannoli A.; Chaouch M.; Kozlov S.; Vallat J.-M.; Tazir M.; Kassouri N.; Szepetowski P.; Hammadouche T.; Vandenberghe A.; Stewart C.L.; Grid D.; Levy N.;
Am. J. Hum. Genet. 70:726-736(2002)
Cited for: VARIANT CMT2B1 CYS-298; FUNCTION;
Disclaimer:
Any medical or genetic information present in this entry is provided for research, educational and informational purposes only. They are not in any way intended to be used as a substitute for professional medical advice, diagnostic, treatment or care.